nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—CYP2C8—Ifosfamide—testicular cancer	0.178	0.279	CbGbCtD
Repaglinide—SLCO1B1—Methotrexate—testicular cancer	0.133	0.208	CbGbCtD
Repaglinide—CYP2C8—Etoposide—testicular cancer	0.0852	0.134	CbGbCtD
Repaglinide—ALB—Methotrexate—testicular cancer	0.0729	0.114	CbGbCtD
Repaglinide—CYP3A4—Ifosfamide—testicular cancer	0.0723	0.113	CbGbCtD
Repaglinide—CYP3A4—Vinblastine—testicular cancer	0.0384	0.0601	CbGbCtD
Repaglinide—CYP3A4—Etoposide—testicular cancer	0.0346	0.0541	CbGbCtD
Repaglinide—CYP3A4—Doxorubicin—testicular cancer	0.0236	0.0369	CbGbCtD
Repaglinide—PPARG—Teniposide—Etoposide—testicular cancer	0.0108	1	CbGdCrCtD
Repaglinide—Hepatobiliary disease—Etoposide—testicular cancer	0.00142	0.00405	CcSEcCtD
Repaglinide—Anaphylactic shock—Bleomycin—testicular cancer	0.00142	0.00405	CcSEcCtD
Repaglinide—Oedema—Bleomycin—testicular cancer	0.00142	0.00405	CcSEcCtD
Repaglinide—Visual impairment—Cisplatin—testicular cancer	0.00142	0.00405	CcSEcCtD
Repaglinide—Thrombocytopenia—Bleomycin—testicular cancer	0.00139	0.00397	CcSEcCtD
Repaglinide—Eye disorder—Cisplatin—testicular cancer	0.00138	0.00393	CcSEcCtD
Repaglinide—Gastrointestinal pain—Vinblastine—testicular cancer	0.00138	0.00392	CcSEcCtD
Repaglinide—Cardiac disorder—Cisplatin—testicular cancer	0.00137	0.0039	CcSEcCtD
Repaglinide—Hypersensitivity—Chlorambucil—testicular cancer	0.00135	0.00386	CcSEcCtD
Repaglinide—Leukopenia—Ifosfamide—testicular cancer	0.00133	0.0038	CcSEcCtD
Repaglinide—Immune system disorder—Cisplatin—testicular cancer	0.00133	0.00379	CcSEcCtD
Repaglinide—Abdominal pain—Vinblastine—testicular cancer	0.00133	0.00379	CcSEcCtD
Repaglinide—Oedema—Dactinomycin—testicular cancer	0.00133	0.00378	CcSEcCtD
Repaglinide—Arrhythmia—Cisplatin—testicular cancer	0.00132	0.00375	CcSEcCtD
Repaglinide—Palpitations—Ifosfamide—testicular cancer	0.00132	0.00375	CcSEcCtD
Repaglinide—Alopecia—Cisplatin—testicular cancer	0.0013	0.00371	CcSEcCtD
Repaglinide—Pruritus—Chlorambucil—testicular cancer	0.0013	0.0037	CcSEcCtD
Repaglinide—Thrombocytopenia—Dactinomycin—testicular cancer	0.0013	0.0037	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00129	0.00369	CcSEcCtD
Repaglinide—Hypertension—Ifosfamide—testicular cancer	0.00128	0.00366	CcSEcCtD
Repaglinide—Erythema—Cisplatin—testicular cancer	0.00128	0.00366	CcSEcCtD
Repaglinide—Malnutrition—Cisplatin—testicular cancer	0.00128	0.00366	CcSEcCtD
Repaglinide—Erythema multiforme—Etoposide—testicular cancer	0.00128	0.00364	CcSEcCtD
Repaglinide—Paraesthesia—Bleomycin—testicular cancer	0.00128	0.00364	CcSEcCtD
Repaglinide—Chest pain—Ifosfamide—testicular cancer	0.00127	0.00361	CcSEcCtD
Repaglinide—Arthralgia—Ifosfamide—testicular cancer	0.00127	0.00361	CcSEcCtD
Repaglinide—Eye disorder—Etoposide—testicular cancer	0.00126	0.0036	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00126	0.00359	CcSEcCtD
Repaglinide—Diarrhoea—Chlorambucil—testicular cancer	0.00126	0.00358	CcSEcCtD
Repaglinide—Cardiac disorder—Etoposide—testicular cancer	0.00125	0.00357	CcSEcCtD
Repaglinide—Hepatic function abnormal—Epirubicin—testicular cancer	0.00125	0.00357	CcSEcCtD
Repaglinide—Hypersensitivity—Vinblastine—testicular cancer	0.00124	0.00353	CcSEcCtD
Repaglinide—Visual disturbance—Methotrexate—testicular cancer	0.00123	0.00352	CcSEcCtD
Repaglinide—Immune system disorder—Etoposide—testicular cancer	0.00122	0.00348	CcSEcCtD
Repaglinide—Anaphylactic shock—Ifosfamide—testicular cancer	0.00121	0.00346	CcSEcCtD
Repaglinide—Oedema—Ifosfamide—testicular cancer	0.00121	0.00346	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Methotrexate—testicular cancer	0.00121	0.00344	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00121	0.00344	CcSEcCtD
Repaglinide—Cardiac failure congestive—Epirubicin—testicular cancer	0.00121	0.00344	CcSEcCtD
Repaglinide—Alopecia—Etoposide—testicular cancer	0.00119	0.0034	CcSEcCtD
Repaglinide—Thrombocytopenia—Ifosfamide—testicular cancer	0.00119	0.00339	CcSEcCtD
Repaglinide—Skin disorder—Ifosfamide—testicular cancer	0.00118	0.00336	CcSEcCtD
Repaglinide—Vomiting—Chlorambucil—testicular cancer	0.00117	0.00333	CcSEcCtD
Repaglinide—Hepatic function abnormal—Doxorubicin—testicular cancer	0.00116	0.0033	CcSEcCtD
Repaglinide—Diarrhoea—Vinblastine—testicular cancer	0.00115	0.00328	CcSEcCtD
Repaglinide—Leukopenia—Cisplatin—testicular cancer	0.00115	0.00327	CcSEcCtD
Repaglinide—Back pain—Etoposide—testicular cancer	0.00114	0.00324	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Epirubicin—testicular cancer	0.00113	0.00322	CcSEcCtD
Repaglinide—Urticaria—Bleomycin—testicular cancer	0.00113	0.00322	CcSEcCtD
Repaglinide—Hypoglycaemia—Epirubicin—testicular cancer	0.00112	0.0032	CcSEcCtD
Repaglinide—Cardiac failure congestive—Doxorubicin—testicular cancer	0.00112	0.00318	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00111	0.00315	CcSEcCtD
Repaglinide—Nausea—Chlorambucil—testicular cancer	0.00109	0.00311	CcSEcCtD
Repaglinide—Paraesthesia—Ifosfamide—testicular cancer	0.00109	0.00311	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00108	0.00309	CcSEcCtD
Repaglinide—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00108	0.00309	CcSEcCtD
Repaglinide—Vomiting—Vinblastine—testicular cancer	0.00107	0.00305	CcSEcCtD
Repaglinide—Headache—Vinblastine—testicular cancer	0.00105	0.003	CcSEcCtD
Repaglinide—Leukopenia—Etoposide—testicular cancer	0.00105	0.003	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00105	0.00299	CcSEcCtD
Repaglinide—Abdominal pain—Dactinomycin—testicular cancer	0.00105	0.00299	CcSEcCtD
Repaglinide—Oedema—Cisplatin—testicular cancer	0.00105	0.00298	CcSEcCtD
Repaglinide—Anaphylactic shock—Cisplatin—testicular cancer	0.00105	0.00298	CcSEcCtD
Repaglinide—Hypersensitivity—Bleomycin—testicular cancer	0.00105	0.00298	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.00105	0.00298	CcSEcCtD
Repaglinide—Constipation—Ifosfamide—testicular cancer	0.00104	0.00296	CcSEcCtD
Repaglinide—Hypoglycaemia—Doxorubicin—testicular cancer	0.00104	0.00296	CcSEcCtD
Repaglinide—Thrombocytopenia—Cisplatin—testicular cancer	0.00103	0.00292	CcSEcCtD
Repaglinide—Skin disorder—Cisplatin—testicular cancer	0.00102	0.0029	CcSEcCtD
Repaglinide—Hypertension—Etoposide—testicular cancer	0.00101	0.00289	CcSEcCtD
Repaglinide—Pruritus—Bleomycin—testicular cancer	0.00101	0.00287	CcSEcCtD
Repaglinide—Chest pain—Etoposide—testicular cancer	0.001	0.00285	CcSEcCtD
Repaglinide—Nausea—Vinblastine—testicular cancer	0.001	0.00285	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000994	0.00283	CcSEcCtD
Repaglinide—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000993	0.00283	CcSEcCtD
Repaglinide—Pancreatitis—Methotrexate—testicular cancer	0.000991	0.00282	CcSEcCtD
Repaglinide—Hypersensitivity—Dactinomycin—testicular cancer	0.000977	0.00278	CcSEcCtD
Repaglinide—Urticaria—Ifosfamide—testicular cancer	0.000965	0.00275	CcSEcCtD
Repaglinide—Abdominal pain—Ifosfamide—testicular cancer	0.00096	0.00274	CcSEcCtD
Repaglinide—Anaphylactic shock—Etoposide—testicular cancer	0.000959	0.00273	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000954	0.00272	CcSEcCtD
Repaglinide—Paraesthesia—Cisplatin—testicular cancer	0.00094	0.00268	CcSEcCtD
Repaglinide—Thrombocytopenia—Etoposide—testicular cancer	0.000939	0.00268	CcSEcCtD
Repaglinide—Skin disorder—Etoposide—testicular cancer	0.000932	0.00266	CcSEcCtD
Repaglinide—Pancreatitis—Epirubicin—testicular cancer	0.000927	0.00264	CcSEcCtD
Repaglinide—Angina pectoris—Epirubicin—testicular cancer	0.000921	0.00263	CcSEcCtD
Repaglinide—Bronchitis—Epirubicin—testicular cancer	0.000909	0.00259	CcSEcCtD
Repaglinide—Diarrhoea—Dactinomycin—testicular cancer	0.000907	0.00258	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000904	0.00258	CcSEcCtD
Repaglinide—Vomiting—Bleomycin—testicular cancer	0.000904	0.00258	CcSEcCtD
Repaglinide—Rash—Bleomycin—testicular cancer	0.000896	0.00255	CcSEcCtD
Repaglinide—Dermatitis—Bleomycin—testicular cancer	0.000895	0.00255	CcSEcCtD
Repaglinide—Hypersensitivity—Ifosfamide—testicular cancer	0.000895	0.00255	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000893	0.00255	CcSEcCtD
Repaglinide—Paraesthesia—Etoposide—testicular cancer	0.000861	0.00245	CcSEcCtD
Repaglinide—Pruritus—Ifosfamide—testicular cancer	0.000859	0.00245	CcSEcCtD
Repaglinide—Pancreatitis—Doxorubicin—testicular cancer	0.000858	0.00244	CcSEcCtD
Repaglinide—Hyperglycaemia—Epirubicin—testicular cancer	0.000853	0.00243	CcSEcCtD
Repaglinide—Angina pectoris—Doxorubicin—testicular cancer	0.000852	0.00243	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—testicular cancer	0.000852	0.00243	CcSEcCtD
Repaglinide—Nausea—Bleomycin—testicular cancer	0.000844	0.00241	CcSEcCtD
Repaglinide—Vomiting—Dactinomycin—testicular cancer	0.000843	0.0024	CcSEcCtD
Repaglinide—Bronchitis—Doxorubicin—testicular cancer	0.000842	0.0024	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000836	0.00238	CcSEcCtD
Repaglinide—Rash—Dactinomycin—testicular cancer	0.000836	0.00238	CcSEcCtD
Repaglinide—Diarrhoea—Ifosfamide—testicular cancer	0.000831	0.00237	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Etoposide—testicular cancer	0.000828	0.00236	CcSEcCtD
Repaglinide—Jaundice—Epirubicin—testicular cancer	0.000822	0.00234	CcSEcCtD
Repaglinide—Constipation—Etoposide—testicular cancer	0.00082	0.00234	CcSEcCtD
Repaglinide—Urinary tract infection—Epirubicin—testicular cancer	0.00082	0.00234	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—testicular cancer	0.000809	0.0023	CcSEcCtD
Repaglinide—Hepatobiliary disease—Epirubicin—testicular cancer	0.000797	0.00227	CcSEcCtD
Repaglinide—Sinusitis—Epirubicin—testicular cancer	0.000791	0.00225	CcSEcCtD
Repaglinide—Hyperglycaemia—Doxorubicin—testicular cancer	0.000789	0.00225	CcSEcCtD
Repaglinide—Nausea—Dactinomycin—testicular cancer	0.000787	0.00224	CcSEcCtD
Repaglinide—Gastrointestinal pain—Etoposide—testicular cancer	0.000784	0.00224	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—testicular cancer	0.000779	0.00222	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000773	0.0022	CcSEcCtD
Repaglinide—Vomiting—Ifosfamide—testicular cancer	0.000772	0.0022	CcSEcCtD
Repaglinide—Hypersensitivity—Cisplatin—testicular cancer	0.000772	0.0022	CcSEcCtD
Repaglinide—Rash—Ifosfamide—testicular cancer	0.000766	0.00218	CcSEcCtD
Repaglinide—Dermatitis—Ifosfamide—testicular cancer	0.000765	0.00218	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—testicular cancer	0.000765	0.00218	CcSEcCtD
Repaglinide—Urticaria—Etoposide—testicular cancer	0.000762	0.00217	CcSEcCtD
Repaglinide—Jaundice—Doxorubicin—testicular cancer	0.00076	0.00217	CcSEcCtD
Repaglinide—Rhinitis—Epirubicin—testicular cancer	0.000759	0.00216	CcSEcCtD
Repaglinide—Abdominal pain—Etoposide—testicular cancer	0.000758	0.00216	CcSEcCtD
Repaglinide—Urinary tract infection—Doxorubicin—testicular cancer	0.000758	0.00216	CcSEcCtD
Repaglinide—Hepatitis—Epirubicin—testicular cancer	0.000757	0.00216	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—testicular cancer	0.000756	0.00215	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—testicular cancer	0.000751	0.00214	CcSEcCtD
Repaglinide—Oedema peripheral—Epirubicin—testicular cancer	0.000746	0.00212	CcSEcCtD
Repaglinide—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000738	0.0021	CcSEcCtD
Repaglinide—Sinusitis—Doxorubicin—testicular cancer	0.000732	0.00209	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—testicular cancer	0.000731	0.00208	CcSEcCtD
Repaglinide—Visual impairment—Epirubicin—testicular cancer	0.000729	0.00208	CcSEcCtD
Repaglinide—Nausea—Ifosfamide—testicular cancer	0.000722	0.00206	CcSEcCtD
Repaglinide—Diarrhoea—Cisplatin—testicular cancer	0.000716	0.00204	CcSEcCtD
Repaglinide—Erythema multiforme—Epirubicin—testicular cancer	0.000716	0.00204	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—testicular cancer	0.000715	0.00204	CcSEcCtD
Repaglinide—Eye disorder—Epirubicin—testicular cancer	0.000707	0.00202	CcSEcCtD
Repaglinide—Hypersensitivity—Etoposide—testicular cancer	0.000707	0.00201	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—testicular cancer	0.000704	0.00201	CcSEcCtD
Repaglinide—Erythema—Methotrexate—testicular cancer	0.000704	0.00201	CcSEcCtD
Repaglinide—Cardiac disorder—Epirubicin—testicular cancer	0.000702	0.002	CcSEcCtD
Repaglinide—Rhinitis—Doxorubicin—testicular cancer	0.000702	0.002	CcSEcCtD
Repaglinide—Hepatitis—Doxorubicin—testicular cancer	0.0007	0.002	CcSEcCtD
Repaglinide—Oedema peripheral—Doxorubicin—testicular cancer	0.00069	0.00197	CcSEcCtD
Repaglinide—Immune system disorder—Epirubicin—testicular cancer	0.000684	0.00195	CcSEcCtD
Repaglinide—Back pain—Methotrexate—testicular cancer	0.000681	0.00194	CcSEcCtD
Repaglinide—Pruritus—Etoposide—testicular cancer	0.000679	0.00193	CcSEcCtD
Repaglinide—Arrhythmia—Epirubicin—testicular cancer	0.000676	0.00193	CcSEcCtD
Repaglinide—Visual impairment—Doxorubicin—testicular cancer	0.000675	0.00192	CcSEcCtD
Repaglinide—Alopecia—Epirubicin—testicular cancer	0.000669	0.00191	CcSEcCtD
Repaglinide—Vomiting—Cisplatin—testicular cancer	0.000666	0.0019	CcSEcCtD
Repaglinide—Erythema multiforme—Doxorubicin—testicular cancer	0.000662	0.00189	CcSEcCtD
Repaglinide—Rash—Cisplatin—testicular cancer	0.00066	0.00188	CcSEcCtD
Repaglinide—Dermatitis—Cisplatin—testicular cancer	0.00066	0.00188	CcSEcCtD
Repaglinide—Malnutrition—Epirubicin—testicular cancer	0.000659	0.00188	CcSEcCtD
Repaglinide—Erythema—Epirubicin—testicular cancer	0.000659	0.00188	CcSEcCtD
Repaglinide—Diarrhoea—Etoposide—testicular cancer	0.000656	0.00187	CcSEcCtD
Repaglinide—Eye disorder—Doxorubicin—testicular cancer	0.000655	0.00187	CcSEcCtD
Repaglinide—Cardiac disorder—Doxorubicin—testicular cancer	0.00065	0.00185	CcSEcCtD
Repaglinide—Back pain—Epirubicin—testicular cancer	0.000637	0.00182	CcSEcCtD
Repaglinide—Immune system disorder—Doxorubicin—testicular cancer	0.000633	0.0018	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—testicular cancer	0.00063	0.0018	CcSEcCtD
Repaglinide—Arrhythmia—Doxorubicin—testicular cancer	0.000626	0.00178	CcSEcCtD
Repaglinide—Nausea—Cisplatin—testicular cancer	0.000622	0.00177	CcSEcCtD
Repaglinide—Alopecia—Doxorubicin—testicular cancer	0.000619	0.00176	CcSEcCtD
Repaglinide—Vomiting—Etoposide—testicular cancer	0.00061	0.00174	CcSEcCtD
Repaglinide—Malnutrition—Doxorubicin—testicular cancer	0.00061	0.00174	CcSEcCtD
Repaglinide—Erythema—Doxorubicin—testicular cancer	0.00061	0.00174	CcSEcCtD
Repaglinide—Rash—Etoposide—testicular cancer	0.000605	0.00172	CcSEcCtD
Repaglinide—Dermatitis—Etoposide—testicular cancer	0.000604	0.00172	CcSEcCtD
Repaglinide—Headache—Etoposide—testicular cancer	0.000601	0.00171	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—testicular cancer	0.000599	0.00171	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—testicular cancer	0.000599	0.00171	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000595	0.0017	CcSEcCtD
Repaglinide—Leukopenia—Epirubicin—testicular cancer	0.00059	0.00168	CcSEcCtD
Repaglinide—Back pain—Doxorubicin—testicular cancer	0.00059	0.00168	CcSEcCtD
Repaglinide—Palpitations—Epirubicin—testicular cancer	0.000582	0.00166	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—testicular cancer	0.000575	0.00164	CcSEcCtD
Repaglinide—Nausea—Etoposide—testicular cancer	0.00057	0.00162	CcSEcCtD
Repaglinide—Hypertension—Epirubicin—testicular cancer	0.000569	0.00162	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—testicular cancer	0.000563	0.0016	CcSEcCtD
Repaglinide—Arthralgia—Epirubicin—testicular cancer	0.000561	0.0016	CcSEcCtD
Repaglinide—Chest pain—Epirubicin—testicular cancer	0.000561	0.0016	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—testicular cancer	0.000558	0.00159	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000557	0.00159	CcSEcCtD
Repaglinide—Leukopenia—Doxorubicin—testicular cancer	0.000546	0.00156	CcSEcCtD
Repaglinide—Palpitations—Doxorubicin—testicular cancer	0.000539	0.00154	CcSEcCtD
Repaglinide—Anaphylactic shock—Epirubicin—testicular cancer	0.000538	0.00153	CcSEcCtD
Repaglinide—Oedema—Epirubicin—testicular cancer	0.000538	0.00153	CcSEcCtD
Repaglinide—Thrombocytopenia—Epirubicin—testicular cancer	0.000527	0.0015	CcSEcCtD
Repaglinide—Hypertension—Doxorubicin—testicular cancer	0.000526	0.0015	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000524	0.00149	CcSEcCtD
Repaglinide—Skin disorder—Epirubicin—testicular cancer	0.000522	0.00149	CcSEcCtD
Repaglinide—Arthralgia—Doxorubicin—testicular cancer	0.000519	0.00148	CcSEcCtD
Repaglinide—Chest pain—Doxorubicin—testicular cancer	0.000519	0.00148	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—testicular cancer	0.000516	0.00147	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000515	0.00147	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—testicular cancer	0.000506	0.00144	CcSEcCtD
Repaglinide—Anaphylactic shock—Doxorubicin—testicular cancer	0.000498	0.00142	CcSEcCtD
Repaglinide—Oedema—Doxorubicin—testicular cancer	0.000498	0.00142	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000496	0.00141	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00049	0.0014	CcSEcCtD
Repaglinide—Thrombocytopenia—Doxorubicin—testicular cancer	0.000487	0.00139	CcSEcCtD
Repaglinide—Skin disorder—Doxorubicin—testicular cancer	0.000483	0.00138	CcSEcCtD
Repaglinide—Paraesthesia—Epirubicin—testicular cancer	0.000483	0.00138	CcSEcCtD
Repaglinide—Dyspepsia—Epirubicin—testicular cancer	0.000473	0.00135	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—testicular cancer	0.00047	0.00134	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000464	0.00132	CcSEcCtD
Repaglinide—Constipation—Epirubicin—testicular cancer	0.00046	0.00131	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—testicular cancer	0.000457	0.0013	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—testicular cancer	0.000454	0.00129	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000453	0.00129	CcSEcCtD
Repaglinide—Paraesthesia—Doxorubicin—testicular cancer	0.000447	0.00127	CcSEcCtD
Repaglinide—Gastrointestinal pain—Epirubicin—testicular cancer	0.00044	0.00125	CcSEcCtD
Repaglinide—Dyspepsia—Doxorubicin—testicular cancer	0.000438	0.00125	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00043	0.00122	CcSEcCtD
Repaglinide—Urticaria—Epirubicin—testicular cancer	0.000427	0.00122	CcSEcCtD
Repaglinide—Constipation—Doxorubicin—testicular cancer	0.000426	0.00121	CcSEcCtD
Repaglinide—Abdominal pain—Epirubicin—testicular cancer	0.000425	0.00121	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—testicular cancer	0.000423	0.00121	CcSEcCtD
Repaglinide—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000407	0.00116	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—testicular cancer	0.000407	0.00116	CcSEcCtD
Repaglinide—Hypersensitivity—Epirubicin—testicular cancer	0.000396	0.00113	CcSEcCtD
Repaglinide—Urticaria—Doxorubicin—testicular cancer	0.000395	0.00113	CcSEcCtD
Repaglinide—Abdominal pain—Doxorubicin—testicular cancer	0.000393	0.00112	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—testicular cancer	0.000393	0.00112	CcSEcCtD
Repaglinide—Pruritus—Epirubicin—testicular cancer	0.00038	0.00108	CcSEcCtD
Repaglinide—Diarrhoea—Epirubicin—testicular cancer	0.000368	0.00105	CcSEcCtD
Repaglinide—Hypersensitivity—Doxorubicin—testicular cancer	0.000367	0.00104	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—testicular cancer	0.000365	0.00104	CcSEcCtD
Repaglinide—Rash—Methotrexate—testicular cancer	0.000362	0.00103	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—testicular cancer	0.000362	0.00103	CcSEcCtD
Repaglinide—Headache—Methotrexate—testicular cancer	0.00036	0.00103	CcSEcCtD
Repaglinide—Pruritus—Doxorubicin—testicular cancer	0.000352	0.001	CcSEcCtD
Repaglinide—Vomiting—Epirubicin—testicular cancer	0.000342	0.000974	CcSEcCtD
Repaglinide—Nausea—Methotrexate—testicular cancer	0.000341	0.000973	CcSEcCtD
Repaglinide—Diarrhoea—Doxorubicin—testicular cancer	0.00034	0.00097	CcSEcCtD
Repaglinide—Rash—Epirubicin—testicular cancer	0.000339	0.000966	CcSEcCtD
Repaglinide—Dermatitis—Epirubicin—testicular cancer	0.000339	0.000965	CcSEcCtD
Repaglinide—Headache—Epirubicin—testicular cancer	0.000337	0.00096	CcSEcCtD
Repaglinide—Nausea—Epirubicin—testicular cancer	0.000319	0.00091	CcSEcCtD
Repaglinide—Vomiting—Doxorubicin—testicular cancer	0.000316	0.000902	CcSEcCtD
Repaglinide—Rash—Doxorubicin—testicular cancer	0.000314	0.000894	CcSEcCtD
Repaglinide—Dermatitis—Doxorubicin—testicular cancer	0.000313	0.000893	CcSEcCtD
Repaglinide—Headache—Doxorubicin—testicular cancer	0.000312	0.000888	CcSEcCtD
Repaglinide—Nausea—Doxorubicin—testicular cancer	0.000296	0.000842	CcSEcCtD
